These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11959048)

  • 1. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.
    Imazio M; Bobbio M; Broglio F; Benso A; Podio V; Valetto MR; Bisi G; Ghigo E; Trevi GP
    Eur J Heart Fail; 2002 Mar; 4(2):185-91. PubMed ID: 11959048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy.
    Broglio F; Benso A; Valetto MR; Gottero C; Quaranta L; Podio V; Arvat E; Bobbio M; Bisi G; Ghigo E
    Endocrine; 2001 Feb; 14(1):105-8. PubMed ID: 11322491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.
    Broglio F; Guarracino F; Benso A; Gottero C; Prodam F; Granata R; Avogadri E; Muccioli G; Deghenghi R; Ghigo E
    Eur J Pharmacol; 2002 Jul; 448(2-3):193-200. PubMed ID: 12144941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac effects of hexarelin in hypopituitary adults.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Aimaretti G; Pelosi E; Del Rio G; Muccioli G; Ong H; Boghen MF; Deghenghi R; Ghigo E
    Eur J Pharmacol; 1999 Sep; 381(1):31-8. PubMed ID: 10528131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats.
    Rossoni G; De Gennaro Colonna V; Bernareggi M; Polvani GL; Müller EE; Berti F
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):260-5. PubMed ID: 9700988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Del Rio G; Arvat E; Boghen MF; Deghenghi R; Muccioli G; Ong H; Ghigo E
    J Endocrinol Invest; 1999 Apr; 22(4):266-72. PubMed ID: 10342360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.
    Rossoni G; Locatelli V; Gennaro Colonna Vd ; Müller EE; Berti F
    Pharmacol Res; 2000 Aug; 42(2):129-36. PubMed ID: 10887041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional myocardial metabolic rate of oxygen measured by O2-15 inhalation and positron emission tomography in patients with cardiomyopathy.
    Agostini D; Iida H; Takahashi A; Tamura Y; Henry Amar M; Ono Y
    Clin Nucl Med; 2001 Jan; 26(1):41-9. PubMed ID: 11139052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional heterogeneity of decreased myocardial norepinephrine and increased lipid peroxidation levels in patients with end-stage failing heart secondary to dilated or ischemic cardiomyopathy.
    Rochette L; Tatou E; Vergely C; Maupoil V; Bouchot O; Mossiat C; Jazayeri S; Benkhadra S; Brenot R; Girard C; David M
    J Heart Lung Transplant; 2008 Jul; 27(7):767-74. PubMed ID: 18582807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sympathetic denervation is associated with microvascular dysfunction in non-infarcted myocardium in patients with cardiomyopathy.
    Rijnierse MT; Allaart CP; de Haan S; Harms HJ; Huisman MC; Wu L; Beek AM; Lammertsma AA; van Rossum AC; Knaapen P
    Eur Heart J Cardiovasc Imaging; 2015 Jul; 16(7):788-98. PubMed ID: 25711350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone-independent cardioprotective effects of hexarelin in the rat.
    Locatelli V; Rossoni G; Schweiger F; Torsello A; De Gennaro Colonna V; Bernareggi M; Deghenghi R; Müller EE; Berti F
    Endocrinology; 1999 Sep; 140(9):4024-31. PubMed ID: 10465272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythrocytoses in patients with dilated and ischemic cardiomyopathy.].
    Chepurnaya AN; Safuanova GS; Nikulicheva VI; Lekhmus TY; Rakhmatullina AR
    Klin Lab Diagn; 2020; 65(4):222-227. PubMed ID: 32227727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.
    Gasperi M; Aimaretti G; Scarcello G; Corneli G; Cosci C; Arvat E; Martino E; Ghigo E
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2633-7. PubMed ID: 10443652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction.
    La Vecchia L; Zanolla L; Varotto L; Bonanno C; Spadaro GL; Ometto R; Fontanelli A
    Am Heart J; 2001 Jul; 142(1):181-9. PubMed ID: 11431676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy.
    Besler C; Urban D; Watzka S; Lang D; Rommel KP; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
    Eur J Heart Fail; 2016 Dec; 18(12):1442-1451. PubMed ID: 27292200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathy.
    Shen YT; Lynch JJ; Hargreaves RJ; Gould RJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):815-20. PubMed ID: 12750438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy.
    Sugioka K; Hozumi T; Takemoto Y; Ehara S; Ogawa K; Iwata S; Oe H; Matsumura Y; Otsuka R; Yoshiyama M; Yoshikawa J
    Am Heart J; 2007 Jun; 153(6):1080.e1-6. PubMed ID: 17540213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study.
    Kwon DH; Halley CM; Carrigan TP; Zysek V; Popovic ZB; Setser R; Schoenhagen P; Starling RC; Flamm SD; Desai MY
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):34-44. PubMed ID: 19356530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical treatment of patients with ischemic cardiomyopathy: the significance of right ventricular function.
    Gureev SV; Kasakov EN; Kormer AY; Ostroumov EN; Shumakov VI
    Heart Surg Forum; 1999; 2(4):330-7. PubMed ID: 11276496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
    Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M
    Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.